IBIS Therapeutics
Accelerating drug discovery through Molecular Fingerprint™ Platform
The only AI-based firm providing integrated solutions for:
Novel Drug Discovery
Selectivity and Safety Assessment
Phenotypic Target Deconvolution
Polypharmacology Prediction
Currently, the 22,000 off-targets and co-targets in the human genome - including all their mutations and variants - are addressed individually
The Problem
A narrowed view leads to a lack of on-target efficacy and unwanted off-target toxicity
The Solution
01
Hit and Lead Finding
02
Lead Optimization
_edited.png)
03
Animal Trials
04
Human Trials
Engagement
Collaborative Research
-
Investigate use of Ibis safety profiling across multiple projects and therapeutic areas
-
Generate machine learning models for toxicity profiling using Ibis Molecular Fingerprint™ Platform
Partnered Discovery
Discovery Services
-
Prioritize compounds for synthesis based upon off-target safety profiles
-
Explore effects of various target mutations upon drug binding
-
Deconvolute targets from phenotypic assays
-
Ibis out-licenses dug-target-disease combinations for drug repurposing
-
Ibis out-licenses novel preclinical assets developed in-house